Navigation Links
Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
Date:3/4/2013

Toronto, Canada (PRWEB) March 04, 2013

With the advent of direct acting antiviral agents for the Hepatitis C virus (HCV), there has been a concerted effort to offer broad testing services and capabilities to assist clients at every stage of drug development. From lead compound optimization and resistance profiling to Phase IV marketing studies, LabCorp and its specialty testing laboratories offer specialized, proprietary testing. In fact, LabCorp offers global central laboratory testing services to support HCV trials around the world.

In this webinar, a thorough overview of currently available HCV capabilities will be presented, including:

  •     Technical overview of HCV assay services, including resistance testing (mutation detection and replicon-based DAA susceptibility assays), viral load assays, genotype/subtype characterization and IL28B allele testing
  •     Appropriate timing and circumstances for each specific test
  •     How these assays can be used to support regulatory filings
  •     How LabCorp’s global reach can help clients conduct more cost-effective clinical trials

The presentation will also highlight ongoing and future HCV assay development activities, such as the implementation of next generation sequencing platforms and the expanded presence in China, Southeast Asia and Europe.

For more information about this event or to register, visit: http://xtks.in/xto575-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10472827.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. CNIO researchers take part in the most comprehensive personalized medicine study performed to date
2. Comprehensive Resource for Food Safety Diagnostics – Romer Labs Launches New Website
3. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
4. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
5. CIVCO to Present Comprehensive Motion Management Solutions at ASTRO 2012 Booth #10003
6. Dr. Ross Kaplan Offers New Comprehensive Acne Package Treatment for Acne and Acne Scarring
7. Taylor-Wharton CryoScience 'Partners For Life' Awards Liquid Nitrogen Freezer to Comprehensive Cancer Center at University of Alabama at Birmingham
8. Rigaku introduces the world’s most comprehensive biological SAXS system for the home lab
9. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Symic Bio, a biopharmaceutical company focused on ... therapeutics, announced today the completion of enrollment for the ... The trial will evaluate the safety and efficacy of ... of restenosis following angioplasty. "We,re pleased ... said Nathan Bachtell , M.D., Chief Medical Officer ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or ... China, today announced its financial results for the fourth quarter ... 2016 Financial Highlights Total sales in ... terms, or increased by 13.6% in USD terms to $77.6 ... Gross profit increased by 13.3% to $46.8 ...
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
(Date:2/7/2017)... Feb. 7, 2017   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... its innovative, highly flexible and award winning eClinical solution, ... iMedNet is a proven Software-as-a-Service (SaaS) clinical ... Capture (EDC), but also delivers an entire suite of ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
Breaking Biology News(10 mins):